Investigational drug · Phase 3
Kedrion IVIG 10%
Also called: KIg 10, Immune globulin 10% for administration, QIVIGY
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Primary Immunodeficiency Disease, Chronic Primary Immune Thrombocytopenia (ITP), Chronic Inflammatory Demyelinating Polyneuropathy.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
6
Any phase or sponsor naming "Kedrion IVIG 10%"
First trial start
2021
Mar 31, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Kedrion IVIG 10%", any sponsor or status.
Conditions studied
As listed on its trial records.
- Primary Immunodeficiency Disease
- Chronic Primary Immune Thrombocytopenia (ITP)
- Chronic Inflammatory Demyelinating Polyneuropathy
- Stiff Person Syndrome
Approved drugs for the same conditions: Immune thrombocytopenia · Hematology and blood cancers · Cardiovascular and metabolic · Neurology · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "Kedrion IVIG 10%" as an intervention, largest first.
- A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% KIg10 (QIVIGY) in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Pivotal-lookingRecruiting
Kedrion S.p.A.Industry
NCT06752356 · 161 participants (planned) · Start Nov 2026 · Primary completion Dec 20, 2027
Drug: Immune globulin (human) 10% solution for intravenous administration · For: Chronic Inflammatory Demyelinating Polyneuropathy
Sites: Stamford, Connecticut; Miami, Florida; Pembroke Pines, Florida · 6 sites in all
- Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in PID PatientsPivotal-lookingCompleted
Kedrion S.p.A.Industry
NCT03961009 · 47 participants · Start Apr 30, 2019 · Primary completion Dec 21, 2020
Drug: Kedrion IVIG 10% · For: Primary Immunodeficiency Disease
Sites: North Palm Beach, Florida; Chicago, Illinois; Overland Park, Kansas · 11 sites in all
- Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID)Pivotal-lookingCompleted
Kedrion S.p.A.Industry
NCT01581593 · 45 participants · Start Nov 12, 2012 · Primary completion Aug 27, 2014
Drug: Kedrion IVIG 10% · For: Primary Immunodeficiency; Agammaglobulinemia; Hypogammaglobulinemia and 1 more
Sites: Little Rock, Arkansas; North Palm Beach, Florida; Atlanta, Georgia · 15 sites in all
- A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)Pivotal-lookingRecruiting
Kedrion S.p.A.Industry
NCT07059000 · 40 participants (planned) · Start Aug 13, 2025 · Primary completion Dec 2026
Drug: Kedrion IVIG 10% · For: Chronic Primary Immune Thrombocytopenia (ITP)
Sites: Los Angeles, California; Shirley, New York; Greenville, North Carolina · 28 sites in all
- A Study Investigating Intravenous Human Normal Immune Globulin 10% in Adults With Stiff Person SyndromePivotal-lookingNot yet recruiting
Kedrion S.p.A.Industry
NCT07552987 · 38 participants (planned) · Start Nov 2026 · Primary completion Jan 2028
Drug: Kedrion IVIg 10%; Human Albumin · For: Stiff Person Syndrome
- Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10)Pivotal-lookingActive, not recruiting
Kedrion S.p.A.Industry
NCT04944979 · 30 participants (planned) · Start Mar 31, 2021 · Primary completion Dec 2026
Drug: Kedrion IVIG 10% · For: Primary Immunodeficiency Disease
Sites: San Francisco, California; Centennial, Colorado; St. Petersburg, Florida · 21 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Safety and tolerability of a new intravenous immunoglobulin 10% in patients with primary immunodeficiency.
Crea R, Perez E, Roifman CM · Immunotherapy 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.